Want to see GB:AGY full AI Analyst Report?
Total Valuation
Allergy Therapeutics has a market cap or net worth of £443.28M. The enterprise value is 394.82M .
Market Cap£443.28M
Enterprise Value394.82M
Share Statistics
Allergy Therapeutics has 6,332,530,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,332,530,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Allergy Therapeutics’s return on equity (ROE) is 1.42 and return on invested capital (ROIC) is -69.33%.
Return on Equity (ROE)1.42
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-69.33%
Return on Capital Employed (ROCE)-0.73
Revenue Per Employee89.94K
Profits Per Employee-64.05K
Employee Count612
Asset Turnover0.81
Inventory Turnover2.15
Valuation Ratios
The current PE Ratio of Allergy Therapeutics is ―. Allergy Therapeutics’s PEG ratio is 0.44.
PE Ratio―
PS Ratio6.88
PB Ratio-13.44
Price to Fair Value-13.44
Price to FCF-11.85
Price to Operating Cash Flow-11.15
PEG Ratio0.44
Income Statement
In the last 12 months, Allergy Therapeutics had revenue of 55.04M and earned -40.13M in profits. Earnings per share was -0.01.
Revenue55.04M
Gross Profit25.13M
Operating Income-29.50M
Pretax Income-40.44M
Net Income-40.13M
EBITDA-29.43M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -32.80M and capital expenditures -4.55M, giving a free cash flow of -37.34M billion.
Operating Cash Flow-32.80M
Free Cash Flow-37.34M
Free Cash Flow per Share>-0.01
Dividends & Yields
Allergy Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.65
52-Week Price Change-11.95%
50-Day Moving Average9.22
200-Day Moving Average9.89
Relative Strength Index (RSI)33.12
Average Volume (3m)460.33K
Important Dates
Allergy Therapeutics upcoming earnings date is Sep 24, 2026, TBA (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateSep 24, 2026
Ex-Dividend Date―
Financial Position
Allergy Therapeutics as a current ratio of 1.28, with Debt / Equity ratio of 629.58%
Current Ratio1.28
Quick Ratio0.76
Debt to Market Cap0.14
Net Debt to EBITDA-1.61
Interest Coverage Ratio-4.31
Taxes
In the past 12 months, Allergy Therapeutics has paid -312.00K in taxes.
Income Tax-312.00K
Effective Tax Rate<0.01
Enterprise Valuation
Allergy Therapeutics EV to EBITDA ratio is -14.48, with an EV/FCF ratio of -13.33.
EV to Sales7.74
EV to EBITDA-14.48
EV to Free Cash Flow-13.33
EV to Operating Cash Flow-14.84
Balance Sheet
Allergy Therapeutics has £10.08M in cash and marketable securities with £26.75M in debt, giving a net cash position of -£16.67M billion.
Cash & Marketable Securities£10.08M
Total Debt£26.75M
Net Cash-£16.67M
Net Cash Per Share>-£0.01
Tangible Book Value Per Share>-£0.01
Margins
Gross margin is 41.17%, with operating margin of -53.60%, and net profit margin of -72.91%.
Gross Margin41.17%
Operating Margin-53.60%
Pretax Margin-73.48%
Net Profit Margin-72.91%
EBITDA Margin-53.46%
EBIT Margin-61.04%
Analyst Forecast
The average price target for Allergy Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast2.94%
EPS Growth Forecast-32.00%